期刊
PHARMACOLOGY & THERAPEUTICS
卷 201, 期 -, 页码 181-201出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2019.05.016
关键词
Protein phosphatase 2A; Inflammation; Cancer; Neurodegeneration; Alzheimer's disease; Multiple sclerosis
资金
- Medical Research Council UK [G0800207]
- Versus Arthritis [21802]
- Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE) award from Versus Arthritis
- MRC [MR/S002871/1] Funding Source: UKRI
Protein phosphatase 2A (PP2A) is a highly complex heterotrimeric enzyme that catalyzes the selective removal of phosphate groups from protein serine and threonine residues. Emerging evidence suggests that it functions as a tumor suppressor by constraining phosphorylation-dependent signalling pathways that regulate cellular transformation and metastasis. Therefore, PP2A-activating drugs (PADs) are being actively sought and investigated as potential novel anti-cancer treatments. Here we explore the concept that PP2A also constrains inflammatory responses through its inhibitory effects on various signalling pathways, suggesting that PADs may be effective in the treatment of inflammation-mediated pathologies. (C) 2019 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据